Astellas Venture Management

Astellas Venture Management

$79,500,000 Venture capital (Series B)
PE Hub

Oncorus scores $79.5 mln Series B


At Verastem, Infinity’s Former Blood Cancer Drug Heads to FDA

$38,600,000 Venture capital (Series C)
Xconomy , vcaonline

Effector Raises $38.6M to Advance New Class of Anti-Cancer Drugs

Funding Health Science
£4,000,000 Venture capital (Series A)
biospace , FinSMEs

Oncorus Announces Additional Series A Financing Support From Astellas Venture Management LLC

Funding Health

Verastem Takes a Low-Cost Flier on Infinity’s Blood Cancer Drug

Health Science
$37,000,000 Venture capital (Series B)
MedCity News , FinSMEs , Xconomy , +1

Startup targeting protein degradation in cancer raises $37M

$43,000,000 Venture capital (Series B)

Tizona Therapeutics Closes $43M Series B Funding

Health Funding Science
$40,000,000 Venture capital (Series B)
The San Diego Union-Tribune

Effector Therapeutics raises $40 million

Science Health Funding

Verastem Sinks as Mesothelioma Study Halted For Futility